Intellectual property The rate of royalty applied in a given case is determined by various factors, the most notable of which are: :* Market drivers and demand structure :* Territorial extent of rights :* Exclusivity of rights :* Level of innovation and stage of development (see
The Technology Life Cycle) :* Sustainability of the technology :* Degree and competitive availability of other technologies :* Inherent risk :* Strategic need :* The portfolio of rights negotiated :* Fundability :* Deal-reward structure (negotiation strength) To correctly gauge royalty rates, the following criteria must be taken into consideration: :* The transaction is at "
arm's length" :* There is a willing buyer and a willing seller :* The transaction is not under compulsion
Rate determination and illustrative royalties There are three general approaches to assess the applicable royalty rate in the licensing of intellectual property. They are • The Cost Approach • The Comparable Market Approach • The Income Approach For a fair evaluation of the royalty rate, the relationship of the parties to the contract should: :– be at "arm's length" (related parties such as the subsidiary and the parent company need to transact as though they were independent parties) :– be viewed as acting free and without compulsion
Cost approach The Cost Approach considers the several elements of cost that may have been entered to create the intellectual property and to seek a royalty rate that will recapture the expense of its development and obtain a return that is commensurate with its expected life. Costs considered could include R&D expenditures, pilot-plant and test-marketing costs, technology upgrading expenses,
patent application expenditure and the like. The method has limited utility since the technology is not priced competitively on "what the market can bear" principles or in the context of the price of similar technologies. More importantly, by lacking optimization (through additional expense), it may earn benefits below its potential. However, the method may be appropriate when a technology is licensed out during its R&D phase as happens with
venture capital investments or it is licensed out during one of the stages of
clinical trials of a pharmaceutical. In the former case, the venture capitalist obtains an equity position in the company (developing the technology) in exchange for financing a part of the development cost (recovering it, and obtaining an appropriate margin, when the company gets acquired or it goes public through the
IPO route). Recovery of costs, with opportunity of gain, is also feasible when development can be followed stage-wise as shown below for a pharmaceutical undergoing clinical trials (the licensee pays higher royalties for the product as it moves through the normal stages of its development): A similar approach is used when
custom software is licensed (an in-license, i.e. an incoming license). The product is accepted on a royalty schedule depending on the software meeting set stage-wise specifications with acceptable error levels in performance tests.
Comparable market approach Here the cost and the risk of development are disregarded. The royalty rate is determined from comparing competing or similar technologies in an industry, modified by considerations of useful "remaining life" of the technology in that industry and contracting elements such as exclusivity provisions, front-end royalties, field of use restrictions, geographic limitations and the "technology bundle" (the mix of patents, know-how, trade-mark rights, etc.) accompanying it. Economist J. Gregory Sidak explains that comparable licenses, when selected correctly, "reveal what the licensor and the licensee consider to be fair compensation for the use of the patented technology" and thus "will most accurately depict the price that a licensee would willingly pay for that technology." The
Federal Circuit has on numerous occasions confirmed that the comparable market approach is a reliable methodology to calculate a reasonable royalty. Although widely used, the prime difficulty with this method is obtaining access to data on comparable technologies and the terms of the agreements that incorporate them. Fortunately, there are several recognized organizations (see "Royalty Rate Websites" listed at the end of this article) who have comprehensive information on both royalty rates and the principal terms of the agreements of which they are a part. There are also IP-related organizations, such as the
Licensing Executives Society, which enable its members to access and share privately assembled data. The two tables shown below are drawn, selectively, from information that is available with an IP-related organization and on-line. The first depicts the range and distribution of royalty rates in agreements. The second shows the royalty rate ranges in select technology sectors (latter data sourced from: Dan McGavock of IPC Group, Chicago, USA). :: ::: Commercial sources also provide information that is invaluable for making comparisons. The following table provides typical information that is obtainable, for instance, from Royaltystat: :::::Sample License Parameters
Reference: 7787
Effective Date: 1 October 1998
SIC Code: 2870
SEC Filed Date: 26 July 2005
SEC Filer: Eden Bioscience Corp
Royalty Rate: 2.000 (%)
SEC Filing: 10-Q
Royalty Base: Net Sales
Agreement Type: Patent
Exclusive: Yes
Licensor: Cornell Research Foundation, Inc.
Licensee: Eden Bioscience Corp.
Lump-Sum Pay: Research support is $150,000 for 1 year.
Duration: 17-year(s)
Territory: Worldwide Coverage : Exclusive patent license to make, have made, use and sell products incorporating
biological materials, including genes, proteins and peptide fragments, expression systems, cells, and antibodies, for the field of plant disease The comparability between transactions requires a comparison of the significant economic conditions that may affect the contracting parties: • Similarity of geographies • Relevant date • Same industry • Market size and its economic development; • Contracting or expanding markets • Market activity: whether wholesale, retail, other • Relative market shares of contracting entities • Location-specific costs of production and distribution • Competitive environment in each geography • Fair alternatives to contracting parties
Income approach The Income approach focuses on the licensor estimating the profits generated by the licensee and obtaining an appropriate share of the generated profit. It is unrelated to costs of technology development or the costs of competing technologies. The approach requires the licensee (or licensor): (a) to generate a cash-flow projection of incomes and expenses over the life-span of the license under an agreed scenario of incomes and costs (b) determining the
Net Present Value, NPV of the profit stream, based on a selected
discount factor, and c) negotiating the division of such profit between the licensor and the licensee. The NPV of a future income is always lower than its current value because an income in the future is attended by risk. In other words, an income in the future needs to be discounted, in some manner, to obtain its present equivalent. The factor by which a future income is reduced is known as the 'discount rate'. Thus, $1.00 received a year from now is worth $0.9091 at a 10%
discount rate, and its discounted value will be still lower two years down the line. The actual discount factor used depends on the risk assumed by the principal gainer in the transaction. For instance, a mature technology worked in different geographies, will carry a lower risk of non-performance (thus, a lower discount rate) than a technology being applied for the first time. A similar situation arises when there is the option of working the technology in one of two different regions; the risk elements in each region would be different. The method is treated in greater detail, using illustrative data, in
Royalty Assessment. The licensor's share of the income is usually set by the "25% rule of thumb", which is said to be even used by tax authorities in the US and Europe for arm's-length transactions. The share is on the operating profit of the licensee firm. Even where such division is held contentious, the rule can still be the starting point of negotiations. Following are three aspects that are important for the profit: :(a) the profit that accrues to the licensee may not arise solely through the engine of the technology. There are returns from the mix of assets it employs such as fixed and working capital and the returns from intangible assets such as distribution systems, trained workforce, etc. Allowances need to be made for them. :(b) profits are also generated by thrusts in the general economy, gains from infrastructure, and the basket of licensed rights – patents, trademark, know-how. A lower royalty rate may apply in an advanced country where large market volumes can be commanded, or where protection to the technology is more secure than in an emerging economy (or perhaps, for other reasons, the inverse). :(c) the royalty rate is only one aspect of the negotiation. Contractual provisions such as an exclusive license, rights to sub-license, warranties on the performance of technology etc may enhance the advantages to the licensee, which is not compensated by the 25% metric. The basic advantage of this approach, which is perhaps the most widely applied, is that the royalty rate can be negotiated without comparative data on how other agreements have been transacted. In fact, it is almost ideal for a case where precedent does not exist. It is, perhaps, relevant to note that the
IRS also uses these three methods, in modified form, to assess the attributable income, or division of income, from a royalty-based transaction between a US company and its foreign subsidiary (since
US law requires that a foreign subsidiary pay an appropriate royalty to the
parent company).
Other compensation modes Royalties are only one among many ways of compensating owners for use of an asset. Others include: :*buying the asset outright, possibly with a
leaseback arrangement :*offering the licensor an
equity position in the licensee company :*staged
milestone payments (as in
drug development and commissioned software arrangements) :*
lump sum payment made to the licensor in one or more installments :*
cross-licensing agreements with or without cash payments, and :*entering into a
strategic alliance or Joint Venture. In discussing the licensing of Intellectual Property, the terms
valuation and
evaluation need to be understood in their rigorous terms. Evaluation is the process of assessing a license in terms of the specific metrics of a particular negotiation, which may include its circumstances, the geographical spread of licensed rights, product range, market width, licensee competitiveness, growth prospects, etc. On the other hand, valuation is the
fair market value (FMV) of the asset – trademark, patent or know-how – at which it can be sold between a willing buyer and willing seller in the context of best awareness of circumstances. The FMV of the IP, where assessable, may itself be a metric for evaluation. If an emerging company is listed on the
stock market, the
market value of its intellectual property can be estimated from the data of the
balance sheet using the equivalence: Market Capitalization = Net
Working capital + Net
Fixed assets + Routine
Intangible assets + IP where the IP is the residual after deducting the other components from the market valuation of the stock. One of the most significant intangibles may be the work-force. The method may be quite useful for valuing trademarks of a listed company if it is mainly or the only IP in play (franchising companies). == See also ==